Overexpression of Batf induces an apoptotic defect and an associated lymphoproliferative disorder in mice

Cell Death and Disease

Volumn 3, Issue 5, 2012, Pages

  Logan, M R ^a,b   Jordan Williams, K L ^a   Poston, S ^a   Liao, J ^a   Taparowsky, E J ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Purdue University   (United States)

Author keywords

ACAD; AP 1; Batf; Lymphoproliferative disorder; Transgenic mice

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; CD2 ANTIGEN; HEMAGGLUTININ; PROTEIN BATF; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; BATF PROTEIN, HUMAN; CASPASE 3; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; T LYMPHOCYTE; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ANIMALS; ANTIGENS, CD2; APOPTOSIS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CASPASE 3; DISEASE MODELS, ANIMAL; HEMAGGLUTININS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES; TRANSCRIPTION FACTOR AP-1;

EID: 84861564657     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.49     Document Type: Article

References (36)

1. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-868.
2. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117(Part 25): 5965-5973.
3. Foletta VC, Segal DH, Cohen DR. Transcriptional regulation in the immune system: all roads lead to AP-1. J Leukoc Biol 1998; 63: 139-152.
4. Echlin DR, Tae HJ, Mitin N, Taparowsky EJ. B-ATF functions as a negative regulator of AP-1-mediated transcription and blocks cellular transformation by Ras and Fos. Oncogene 2000; 19: 1752-1763.
5. Williams KL, Nanda I, Lyons GE, Kuo CT, Schmid M, Leiden JM et al. Characterization of murine BATF: a negative regulator of activator protein-1 activity in the thymus. Eur J Immunol 2001; 31: 1620-1627.
6. Ise W, Kohyama M, Schraml BU, Zhang T, Schwer B, Basu U et al. The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat Immunol 2011; 12: 536-543.
7. Schraml BU, Hildner K, Ise W, Lee WL, Smith WA, Solomon B et al. The AP-1 transcription factor Batf controls T(H)17 differentiation. Nature 2009; 460: 405-409.
8. Williams KL, Zullo AJ, Kaplan MH, Brutkiewicz RR, Deppmann CD, Vinson C et al. BATF transgenic mice reveal a role for activator protein-1 in NKT cell development. J Immunol 2003; 170: 2417-2426.
9. Zullo AJ, Benlagha K, Bendelac A, Taparowsky EJ. Sensitivity of NK1.1-negative NKT cells to transgenic BATF defines a role for activator protein-1 in the expansion and maturation of immature NKT cells in the thymus. J Immunol 2007; 178: 58-66.
10. Betz BC, Jordan-Williams KL, Wang C, Kang SG, Liao J, Logan MR et al. Batf coordinates multiple aspects of B and T cell function required for normal antibody responses. J Exp Med 2010; 207: 933-942.
11. Kuroda S, Yamazaki M, Abe M, Sakimura K, Takayanagi H, Iwai Y. Basic leucine zipper transcription factor, ATF-like (BATF) regulates epigenetically and energetically effector CD8 T-cell differentiation via Sirt1 expression. Proc Natl Acad Sci USA 2011; 108: 14885-14889.
12. Lorenzo Y, Provencio M, Lombardia L, Diaz R, Silva J, Herrera M et al. Differential genetic and functional markers of second neoplasias in Hodgkin's disease patients. Clin Cancer Res 2009; 15: 4823-4828.
13. Rasmussen MH, Sorensen AB, Morris DW, Dutra JC, Engelhard EK,Wang CL et al. Tumor model-specific proviral insertional mutagenesis of the Fos/Jdp2/Batf locus. Virology 2005; 337: 353-364.
14. Thornton TM, Zullo AJ, Williams KL, Taparowsky EJ. Direct manipulation of activator protein-1 controls thymocyte proliferation in vitro. Eur J Immunol 2006; 36: 160-169.
15. Kawamoto H, Ohmura K, Fujimoto S, Lu M, Ikawa T, Katsura Y. Extensive proliferation of T cell lineage-restricted progenitors in the thymus: an essential process for clonal expression of diverse T cell receptor beta chains. Eur J Immunol 2003; 33: 606-615.
16. Tanaka N, Kamanaka M, Enslen H, Dong C, Wysk M, Davis RJ et al. Differential involvement of p38 mitogen-activated protein kinase kinases MKK3 and MKK6 in T-cell apoptosis. EMBO Rep 2002; 3: 785-791.
17. Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P. Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol 2002; 14: 354-359.
18. Arnold R, Brenner D, Becker M, Frey CR, Krammer PH. How T lymphocytes switch between life and death. Eur J Immunol 2006; 36: 1654-1658.
19. Bouillet P, O'Reilly LA. CD95, BIM and T cell homeostasis. Nat Rev Immunol 2009; 9: 514-519.
20. Ewings KE, Wiggins CM, Cook SJ. Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle 2007; 6: 2236-2240.
21. Greiner T, Armitage JO, Gross TG. Atypical Lymphoproliferative Diseases. Hematol Am Soc Hematol Educ Program 2000 133-146.
22. Worth A, Thrasher AJ, Gaspar HB. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol 2006; 133: 124-140.
23. Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit Rev Oncol Hematol 2008; 66: 52-64.
24. Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, Kappler J et al. Activated T cell death in vivo mediated by proapoptotic Bcl-2 family member Bim. Immunity 2002; 16: 759-767.
25. Khaled AR, Durum SK. Lymphocide: cytokines and the control of lymphoid homeostasis. Nat Rev Immunol 2002; 2: 817-830.
26. Purushothaman D, Sarin A. Cytokine-dependent regulation of NADPH oxidase activity and the consequences for activated T cell homeostasis. J Exp Med 2009; 206: 1515-1523.
27. Hildeman DA, Mitchell T, Kappler J, Marrack P. T cell apoptosis and reactive oxygen species. J Clin Invest 2003; 111: 575-581.
28. Biswas SC, Shi Y, Sproul A, Greene LA. Pro-apoptotic Bim induction in response to nerve growth factor deprivation requires simultaneous activation of three different death signaling pathways. J Biol Chem 2007; 282: 29368-29374.
29. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 2001; 29: 629-643.
30. Ishihara Y, Ito F, Shimamoto N. Increased expression of c-Fos by extracellular signalregulated kinase activation under sustained oxidative stress elicits BimEL upregulation and hepatocyte apoptosis. FEBS J 2011; 278: 1873-1881.
31. Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol 2007; 171: 263-273.
32. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4 + and CD4-8-T cells in mice and humans. J Exp Med 1994; 180: 1097-1106.
33. Liao J, Humphrey SE, Poston S, Taparowsky EJ. Batf promotes growth arrest and terminal differentiation of mouse myeloid leukemia cells. Mol Cancer Res 2011; 9: 350-363.
34. Johansen LM, Deppmann CD, Erickson KD, Coffin WF 3rd, Thornton TM, Humphrey SE et al. EBNA2 and activated Notch induce expression of BATF. J Virol 2003; 77: 6029-6040.
35. Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K et al. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 2004; 24: 6172-6183.
36. Ohigashi T, Ueno M, Nonaka S, Nakanoma T, Furukawa Y, Deguchi N et al. Tyrosine kinase inhibitors reduce bcl-2 expression and induce apoptosis in androgen-dependent cells. Am J Physiol Cell Physiol 2000; 278: C66-C72.